Evan Y. Yu, MD

Articles

Roundtable Discussion: Yu Explores the Role of Hereditary Germline Testing in Nonmetastatic CRPC

May 19th 2021

During a Targeted Oncology Case-Based Roundtable event, Evan Y. Yu, MD leads a discussion on hereditary germline mutations impact on prostate-cancer risk.

Rapidly Expanding Options in mCRPC

Evan Y. Yu, MD

June 2nd 2020

Setting Realistic Goals With Palliative Therapy in mCRPC

Evan Y. Yu, MD

June 2nd 2020

Significant Impact of COVID-19 on the Treatment of mCRPC

Evan Y. Yu, MD

June 2nd 2020

Pragmatic Considerations for Early Radium-223 in mCRPC

Evan Y. Yu, MD

June 2nd 2020

Overall Survival Data in mCRPC

Evan Y. Yu, MD

June 2nd 2020

Initial Impressions of Patient With High-Risk Localized PC

Evan Y. Yu, MD

June 2nd 2020

Case Review: 66-Year-Old Develops mCRPC

Evan Y. Yu, MD

June 2nd 2020

Case Review: Rationale and Methods in mCRPC

Evan Y. Yu, MD

June 2nd 2020

Evan Y. Yu, MD, discusses the case and subsequent palliative treatment plan for a patient with metastatic castration-resistant prostate cancer.

Key Takeaways from KEYNOTE-365 in Metastatic Castration-Resistant Prostate Cancer

Evan Y. Yu, MD

July 18th 2019

Evan Y. Yu, MD, discussed the key takeaways from the phase Ib/II KEYNOTE-365 trial, which evaluated different novel pembrolizumab (Keytruda) combinations in patients with metastatic castration-resistant prostate cancer.

The Utility of PET Imaging in Prostate Cancer

Evan Y. Yu, MD

January 7th 2014

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.